Repository of Research and Investigative Information

Repository of Research and Investigative Information

Ilam University of Medical Sciences

Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis

Fri May 20 02:42:33 2022

(2017) Hearing loss in Iranian thalassemia major patients treated with deferoxamine: A systematic review and meta-analysis. Caspian Journal of Internal Medicine. pp. 239-249. ISSN 2008-6164

Full text not available from this repository.

Official URL: http://apps.webofknowledge.com/InboundService.do?F...

Abstract

Background: Hearing disorders are reported in thalassemia patients treated with deferoxamine. This study aimed to assess hearing loss in Iranian thalassemia major patients treated with deferoxamine. Methods: This review article was designed based on PRISMA guidelines. To review the literature, two researchers studied national and international databases including Iranmedex, Magiran, Medlib, SID, Scopus, PubMed, Science Direct, Web of Science and Google Scholar without time limit until May 2017. Cochran's Q test and I-2 index were used to assess the heterogeneity of the studies. The data were analyzed using Comprehensive Meta-Analysis software version 2 and p<0.05 was considered significant. Results: A total of 17 articles involving 1,835 Iranian thalassemia major patients treated with deferoxamine were included in the meta-analysis. The overall prevalence of hearing loss was estimated 27.3 (95 confidence intervals (CI): 19-37.6). The prevalence of sensorineural, conductive and mixed hearing loss was estimated 10.6 (95 CI: 5.7-18.8), 14.6 (95 CI: 10.5-20.6) and 9.1 (95 CI: 5.6-14.6), respectively. No significant differences were noted regarding the relationship hearing loss and mean serum ferritin (P=0.29) and average daily deferoxamine (P=0.30). Meta-regression model showed an increased significance in the prevalence of hearing loss based on the year of studies (p<0.0001). Conclusions: There is a high prevalence of hearing loss in Iranian thalassemia major patients treated with deferoxamine. Therefore, periodic hearing assessments and regular check-ups after the initiation of chelation therapy are necessary.

Item Type: Article
Creators:
CreatorsEmail
Badfar, G.UNSPECIFIED
Mansouri, A.UNSPECIFIED
Shohani, M.UNSPECIFIED
Karimi, H.UNSPECIFIED
Khalighi, Z.UNSPECIFIED
Rahmati, S.UNSPECIFIED
Delpisheh, A.UNSPECIFIED
Veisani, Y.UNSPECIFIED
Soleymani, A.UNSPECIFIED
Azami, M.UNSPECIFIED
Keywords: Hearing loss Thalassemia major Deferoxamine Systematic review Meta-analysis Iran regular chelation-therapy beta-thalassemia desferrioxamine epidemiology ototoxicity prevalence guidelines statement toxicity models General & Internal Medicine
Divisions:
Page Range: pp. 239-249
Journal or Publication Title: Caspian Journal of Internal Medicine
Journal Index: ISI
Volume: 8
Number: 4
Identification Number: https://doi.org/10.22088/cjim.8.4.239
ISSN: 2008-6164
Depositing User: مهندس مهدی شریفی
URI: http://eprints.medilam.ac.ir/id/eprint/358

Actions (login required)

View Item View Item